- Home
- Publications
- Publication Search
- Publication Details
Title
Aktueller Stand zur Systemtherapie bei atopischer Dermatitis
Authors
Keywords
-
Journal
HAUTARZT
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-06-01
DOI
10.1007/s00105-022-05003-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
- (2022) Roselie E. Achten et al. ACTA DERMATO-VENEREOLOGICA
- The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry
- (2022) Angelique N. Voorberg et al. CONTACT DERMATITIS
- Two Phase 3 Trials of Baricitinib for Alopecia Areata
- (2022) Brett King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Facial and neck erythema associated with dupilumab treatment: A systematic review
- (2021) Christine E. Jo et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dupilumab Therapy for Alopecia Areata in Pediatric Patients with Concomitant Atopic Dermatitis
- (2021) Paige L. McKenzie et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Eczema herpeticum in atopic dermatitis
- (2021) Stephan Traidl et al. ALLERGY
- Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
- (2021) Joseph F. Merola et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
- (2021) Thomas Bieber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata
- (2021) Alessio Gambardella et al. Dermatitis
- Dupilumab in eosinophilic cellulitis (Wells’ syndrome) – case report of a potential new treatment option
- (2021) Stephan Traidl et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
- (2021) Andrew Blauvelt et al. JAMA Dermatology
- Upadacitinib-induced remission of allergic asthma: A case report
- (2021) Diana Betancor et al. Journal of Allergy and Clinical Immunology-In Practice
- Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials
- (2021) A. Wollenberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Haarwachstum unter Dupilumab bei Alopecia areata universalis und atopischer Dermatitis
- (2021) L. Reinhold et al. HAUTARZT
- Dupilumab facial redness: histologic characterization on a series of four cases
- (2021) Agnieszka Dybała et al. Immunotherapy
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- (2021) Brett King et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Implementation of dupilumab in routine care of atopic eczema. Results from the German national registry TREATgermany
- (2020) S. Abraham et al. BRITISH JOURNAL OF DERMATOLOGY
- The effectiveness of dupilumab in alopecia areata patients with atopic dermatitis: a case series of seven patients
- (2020) K. Harada et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
- (2020) William J. Sandborn et al. GASTROENTEROLOGY
- Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry
- (2020) Angela L. Bosma et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The current extent of and need for shared decision making in atopic dermatitis and psoriasis in the Netherlands: An online survey study amongst patients and physicians
- (2020) G.E. van der Kraaij et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial
- (2020) Amy S. Paller et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- (2020) Eric L Simpson et al. LANCET
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
- (2020) Jonathan I. Silverberg et al. JAMA Dermatology
- Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
- (2020) A. Wollenberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis
- (2020) Anne-Sofie Halling et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry
- (2020) Lieneke FM. Ariëns et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A phase 2, open‐label study of single dose dupilumab in children aged 6 months to
- (2020) A.S. Paller et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
- (2019) Sarah Faiz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
- (2019) Lawrence F. Eichenfield et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Conjunctivitis in dupilumab clinical trials
- (2019) B. Akinlade et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
- (2019) Claus Bachert et al. LANCET
- Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
- (2019) M. C. Fargnoli et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Baseline characteristics, disease severity and treatment history of Patients with Atopic Dermatitis included in the German AD Registry TREATgermany
- (2019) A Heratizadeh et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis
- (2019) Margitta Worm et al. JAMA Dermatology
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
- (2018) M. de Bruin-Weller et al. BRITISH JOURNAL OF DERMATOLOGY
- Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength
- (2018) Rachael J. Thorneloe et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials
- (2018) Patrick Fleming et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
- (2018) Mario Castro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
- (2018) Reynold A Panettieri et al. Lancet Respiratory Medicine
- Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis
- (2018) Alison D. Treister et al. JAMA Dermatology
- Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis
- (2018) Nicholas K. Mollanazar et al. JAMA Dermatology
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- (2017) Andrew Blauvelt et al. LANCET
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Multidisciplinary interventions in the management of atopic dermatitis
- (2016) Jennifer S. LeBovidge et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started